AlphaMark Advisors’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

AlphaMark Advisors’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-115	Closed	-$11K	–	523
2019 Q2	$11K	Hold	115	–	–	﹤0.01%	330
2019 Q1	$10K	Hold	115	–	–	﹤0.01%	328
2018 Q4	$6K	Hold	115	–	–	﹤0.01%	366
2018 Q3	$9K	Buy	+115	New	+$8.11K	﹤0.01%	364

Other funds holding RETA

CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

AlphaMark Advisors's RETA Position: Q3 2019 in Review

AlphaMark Advisors sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2019, closing a stake of 115 shares — an estimated $11K sold.

AlphaMark Advisors first reported a position in RETA in Q3 2018 and held it in 4 quarters. The position peaked at $11K in Q2 2019. 164 funds tracked by Wall St. Rank hold RETA as of Q3 2019.

AlphaMark Advisors reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2019 after selling out during the quarter.
AlphaMark Advisors sold 115 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2019, an estimated $11K.
AlphaMark Advisors first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q3 2018 and held it in 4 quarters.
AlphaMark Advisors's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $11K in Q2 2019.
164 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2019.

Based on AlphaMark Advisors's 13F filing for Q3 2019, filed 1 Nov 2019.